Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Preliminary Efficacy of VDJ-001 in Rheumatoid Arthritis
NCT05232396Phase 1Completed
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VDJ-001 in rheumatoid arthritis (RA) (4 arms), sponsored by Beijing VDJBio Co., Ltd. Primary endpoints: Safety as measured by patients with adverse events, AUC from time 0 to the time of the last quantifiable concentration and 1 more. Started Mar 2021; status: completed.
02
Drugs
VDJ-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05232396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232396.